Oppenheimer Asset Management Inc. Abb Vie Inc. Transaction History

Oppenheimer Asset Management Inc.

$8.04 Billion
Q3 2024

A detailed history of Oppenheimer Asset Management Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Oppenheimer Asset Management Inc. holds 206,887 shares of ABBV stock, worth $36.3 Million. This represents 0.51% of its overall portfolio holdings.

Number of Shares

206,887

Previous 203,970 1.43%

Holding current value

$36.3 Million

Previous $35 Million 16.78%

% of portfolio

0.51%

Previous 0.46%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	BUY	$163.84 - $199.33 $477,921 - $581,445	2,917 Added 1.43%	206,887 $40.9 Million
Q2 2024 Aug 08, 2024	BUY	$154.79 - $180.76 $8.16 Million - $9.53 Million	52,731 Added 34.87%	203,970 $35 Million
Q1 2024 May 06, 2024	SELL	$159.82 - $182.1 $1.49 Million - $1.69 Million	-9,295 Reduced 5.79%	151,239 $27.5 Million
Q4 2023 Feb 13, 2024	BUY	$137.6 - $154.97 $900,179 - $1.01 Million	6,542 Added 4.25%	160,534 $24.9 Million
Q3 2023 Nov 07, 2023	BUY	$133.59 - $154.65 $1.13 Million - $1.3 Million	8,437 Added 5.8%	153,992 $23 Million
Q2 2023 Aug 02, 2023	SELL	$132.51 - $164.9 $1.58 Million - $1.97 Million	-11,952 Reduced 7.59%	145,555 $19.6 Million
Q1 2023 May 10, 2023	BUY	$144.61 - $166.54 $609,531 - $701,966	4,215 Added 2.75%	157,507 $25.1 Million
Q4 2022 Feb 06, 2023	BUY	$138.31 - $165.87 $1.06 Million - $1.27 Million	7,652 Added 5.25%	153,292 $24.8 Million
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $1.39 Million - $1.59 Million	10,345 Added 7.65%	145,640 $19.5 Million
Q2 2022 Aug 08, 2022	BUY	$137.62 - $174.96 $261,065 - $331,899	1,897 Added 1.42%	135,295 $20.7 Million
Q1 2022 May 12, 2022	SELL	$131.98 - $163.75 $3.27 Million - $4.06 Million	-24,766 Reduced 15.66%	133,398 $21.6 Million
Q4 2021 Feb 02, 2022	SELL	$107.43 - $135.93 $54,681 - $69,188	-509 Reduced 0.32%	158,164 $21.4 Million
Q3 2021 Nov 12, 2021	BUY	$106.4 - $120.78 $467,415 - $530,586	4,393 Added 2.85%	158,673 $17.1 Million
Q2 2021 Aug 03, 2021	BUY	$105.21 - $117.21 $2.03 Million - $2.26 Million	19,286 Added 14.29%	154,280 $17.4 Million
Q1 2021 May 17, 2021	BUY	$102.3 - $112.62 $997,834 - $1.1 Million	9,754 Added 7.79%	134,994 $14.6 Million
Q4 2020 Feb 11, 2021	BUY	$80.49 - $108.67 $166,453 - $224,729	2,068 Added 1.68%	125,240 $13.4 Million
Q3 2020 Nov 13, 2020	BUY	$85.91 - $100.83 $1.12 Million - $1.32 Million	13,055 Added 11.86%	123,172 $10.8 Million
Q2 2020 Aug 11, 2020	BUY	$73.37 - $98.18 $629,514 - $842,384	8,580 Added 8.45%	110,117 $10.8 Million
Q1 2020 May 08, 2020	SELL	$64.5 - $97.79 $1.36 Million - $2.06 Million	-21,058 Reduced 17.18%	101,537 $7.74 Million
Q4 2019 Feb 07, 2020	SELL	$72.13 - $90.25 $15,435 - $19,313	-214 Reduced 0.17%	122,595 $10.9 Million
Q3 2019 Oct 31, 2019	SELL	$62.98 - $75.72 $363,016 - $436,450	-5,764 Reduced 4.48%	122,809 $9.3 Million
Q2 2019 Aug 09, 2019	BUY	$65.7 - $83.98 $3.38 Million - $4.32 Million	51,430 Added 66.67%	128,573 $9.35 Million
Q1 2019 Apr 24, 2019	SELL	$77.14 - $90.79 $892,124 - $1.05 Million	-11,565 Reduced 13.04%	77,143 $6.22 Million
Q4 2018 Jan 30, 2019	SELL	$77.85 - $96.01 $311,244 - $383,847	-3,998 Reduced 4.31%	88,708 $8.18 Million
Q3 2018 Oct 26, 2018	SELL	$88.91 - $98.84 $184,577 - $205,191	-2,076 Reduced 2.19%	92,706 $8.77 Million
Q2 2018 Aug 10, 2018	SELL	$89.78 - $106.23 $214,753 - $254,102	-2,392 Reduced 2.46%	94,782 $8.78 Million
Q1 2018 May 09, 2018	BUY	$92.01 - $123.21 $67,167 - $89,943	730 Added 0.76%	97,174 $9.2 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $6.74 Million - $8.6 Million	96,444	96,444 $8.57 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $310B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.

Account

Oppenheimer Asset Management Inc. Abb Vie Inc. Transaction History